UPDATE: Morgan Stanley Upgrades Alkermes plc to Overweight on New Pipeline Opportunities
January 10, 2013 at 08:19 AM EST
Morgan Stanley upgraded Alkermes plc (NASDAQ: ALKS ) from Equal-weight to Overweight and raised the price target from $21.00 to $26.00. Morgan Stanley noted, "We anticipate improving investor perception as Alkermes transitions from being an outsourced drug delivery tech co. to an innovation engine with higher-value internal candidates. … We
